Sign In
Sign Up
Accessibility Tools
- Mode
- Font Size
  - A ^-
  - A
  - A ⁺
Accessibility

Profile

Blogs

Business

Create Sub Blog

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

2 hours ago -

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Falling wages, soaring energy prices and inflation: It’s beg

3 minutes ago

OpenAI Hires Former White House Cyber Official as Regulators

4 minutes ago

EMVCo Framework Targets Consumer Intent in Agentic Payments

16 minutes ago

Teach For Uganda STEM Fellowship 2026: Fully Funded STEM Tea

27 minutes ago

Comment

CNBC

News Source

About the Author

CNBC is the world leader in business news and real-time financial market coverage. Find fast, actionable information.

Suggested Writers

Matilda Wambua

8.5K articles
UAE Jobs

2.8K articles
Hiring Kenya

1.6K articles
SHAZ-TECH💻 CONNECTIONS

34 articles

Access Semasocial from your phone.

𝗦𝗲𝗺𝗮𝘀𝗼𝗰𝗶𝗮𝗹 𝗶𝘀 𝘄𝗵𝗲𝗿𝗲 𝗽𝗲𝗼𝗽𝗹𝗲 𝗰𝗼𝗻𝗻𝗲𝗰𝘁, 𝗴𝗿𝗼𝘄, 𝗮𝗻𝗱 𝗳𝗶𝗻𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀.
From jobs and gigs to communities, events, and real conversations — we bring people and ideas together in one simple, meaningful space.

Explore

Quick Links

About Us

Nairobi, Kenya
[email protected]
+254103750662

Profile

Blogs

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Related Posts

Comment

Photos